Clinical Trial: MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of chemotherapy with MT-R followed by autologous stem cells transplantation in newly-diagnosed primary central nervous system lymphoma.
Detailed Summary: It's a single center, single arm, prospective clinical trial. Patients younger than 65 years old with primary central nervous system lymphoma will received four cycles of chemotherapy with rituximab plus high-dose methotrexate and temozolomide as induction therapy, and then received consolidation therapy with autologous stem cell transplant for which the conditioning regimen is Carmustine plus thiotepa.
Sponsor: Jun Zhu
Current Primary Outcome: progression-free survival [ Time Frame: 2 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- overall response rate [ Time Frame: 2 years ]
- overall survival [ Time Frame: 2 years ]
- event-free survival [ Time Frame: 2 years ]
Original Secondary Outcome: Same as current
Information By: Peking University
Dates:
Date Received: March 1, 2015
Date Started: May 2014
Date Completion: April 2019
Last Updated: April 10, 2015
Last Verified: April 2015
